Literature DB >> 30658997

Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.

Vincent Wai-Sun Wong1,2, Marie Irles3, Grace Lai-Hung Wong1,2, Sarah Shili3, Anthony Wing-Hung Chan4, Wassil Merrouche3, Sally She-Ting Shu1,2, Juliette Foucher3, Brigitte Le Bail5,6, Wah Kheong Chan7, Henry Lik-Yuen Chan1,2, Victor de Ledinghen3,6.   

Abstract

OBJECTIVE: The latest model of vibration-controlled transient elastography (VCTE) automatically selects M or XL probe according to patients' body built. We aim to test the application of a unified interpretation of VCTE results with probes appropriate for the body mass index (BMI) and hypothesise that this approach is not affected by hepatic steatosis.
DESIGN: We prospectively recruited 496 patients with non-alcoholic fatty liver disease who underwent VCTE by both M and XL probes within 1 week before liver biopsy.
RESULTS: 391 (78.8%) and 433 (87.3%) patients had reliable liver stiffness measurement (LSM) (10 successful acquisitions and IQR:median ratio ≤0.30) by M and XL probes, respectively (p<0.001). The area under the receiver operating characteristic curves was similar between the two probes (0.75-0.88 for F2-4, 0.83-0.91 for F4). When used in the same patient, LSM by XL probe was lower than that by M probe (mean difference 2.3 kPa). In contrast, patients with BMI ≥30 kg/m2 had higher LSM regardless of the probe used. When M and XL probes were used in patients with BMI <30 and ≥30 kg/m2, respectively, they yielded nearly identical median LSM at each fibrosis stage and similar diagnostic performance. Severe steatosis did not increase LSM or the rate of false-positive diagnosis by XL probe.
CONCLUSION: High BMI but not severe steatosis increases LSM. The same LSM cut-offs can be used without further adjustment for steatosis when M and XL probes are used according to the appropriate BMI. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fatty liver; hepatic fibrosis; liver biopsy; liver cirrhosis; nonalcoholic steatohepatitis

Mesh:

Year:  2019        PMID: 30658997     DOI: 10.1136/gutjnl-2018-317334

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  27 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

2.  Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.

Authors:  Anshuman Elhence; Abhinav Anand; Sagnik Biswas; Manas Vaishnav; Rajni Yadav; Prasenjit Das; Rajesh Panwar; Sandeep Agarwal; Shivanand Gamanagatti; Ramesh Kumar
Journal:  Dig Dis Sci       Date:  2022-06-07       Impact factor: 3.199

3.  Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.

Authors:  Narendra S Choudhary; Neeraj Saraf; Swapnil Dhampalwar; Saurabh Mishra; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Prashant Bhangui; Rohan J Chaudhary; Ankur Gupta; Kamal Yadav; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2022-05-05

4.  Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.

Authors:  Thierry Thévenot; Sophie Vendeville; Delphine Weil; Linda Akkouche; Paul Calame; Clémence M Canivet; Claire Vanlemmens; Carine Richou; Jean-Paul Cervoni; Marie-France Seronde; Vincent Di Martino; Jérôme Boursier
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

Review 5.  Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.

Authors:  Raghu Ramanathan; Ahmad Hassan Ali; Jamal A Ibdah
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

6.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

7.  Liver stiffness measurement identifies subclinical myocardial dysfunction in non-advanced non-alcoholic fatty liver disease patients without overt heart disease.

Authors:  Andrea Sonaglioni; Federica Cerini; Antonio Cerrone; Lorenzo Argiento; Gian Luigi Nicolosi; Elisabetta Rigamonti; Michele Lombardo; Maria Grazia Rumi; Mauro Viganò
Journal:  Intern Emerg Med       Date:  2022-03-17       Impact factor: 5.472

Review 8.  Confounding factors of non-invasive tests for nonalcoholic fatty liver disease.

Authors:  Janae Wentong Wai; Charmaine Fu; Vincent Wai-Sun Wong
Journal:  J Gastroenterol       Date:  2020-05-25       Impact factor: 7.527

9.  Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.

Authors:  Tracy Davyduke; Puneeta Tandon; Mustafa Al-Karaghouli; Juan G Abraldes; Mang M Ma
Journal:  Hepatol Commun       Date:  2019-07-29

10.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.

Authors:  Ioan Sporea; Ruxandra Mare; Alina Popescu; Silviu Nistorescu; Victor Baldea; Roxana Sirli; Adina Braha; Alexandra Sima; Romulus Timar; Raluca Lupusoru
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.